A new generation of mouse models of cancer for translational research

Clinical Cancer Research

Volumn 12, Issue 18, 2006, Pages 5274-5276

  Abate Shen, Cory ^a,b  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER MODEL; CANCER PATIENT; CANCER RESEARCH; CANCER SUSCEPTIBILITY; CANCER THERAPY; CARCINOGENESIS; CARCINOMA; EXPERIMENTAL MODEL; GENE DELETION; GENE EXPRESSION; MICROENVIRONMENT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DRUG DESIGN; MICE; MICE, TRANSGENIC; NEOPLASMS;

EID: 33749318558     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0500     Document Type: Review

References (21)

1. Olive KP, Tuveson DA. A "mouse hospital" for preclinical testing of novel cancer therapeutics. Clin Cancer Res. In press 2006.
2. Fomchenko EI, Holland EC. Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res. In press 2006.
3. Carver BS, Pandolfi PP. Mouse modeling in oncological pre-clinical and translational research. Clin Cancer Res. In press 2006.
4. Degenhardt K, White E. A mouse model system to genetically dissect the molecular mechanisms of tumorigenesis. Clin Cancer Res. In press 2006.
5. Singh M, Johnson L. Using genetically engineered mouse models of cancer to aid drug development: an industry perspective. Clin Cancer Res. In press 2006.
6. Rangarajan A, Weinberg RA. Opinion: comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev Cancer 2003;3:952-9.
7. Van Dyke T, Jacks T. Cancer modeling in the modern era: progress and challenges. Cell 2002;108:135-44.
8. Holland EC. Mouse models of human cancer. Hoboken (NJ): John Wiley & Sons, Inc.: 2004. p. 475.
9. DePinho RA, Jacks T. Introduction. The laboratory mouse in cancer research. Semin Cancer Biol 2001;11:175-6.
10. Bowman T, Symonds H, Gu L, Yin C, Oren M, Van Dyke T. Tissue-specific inactivation of p53 tumor suppression in the mouse. Genes Dev 1996;10:826-35.
11. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995;92:3439-43.
12. Hanahan D. Heritable formation of pancreatic β-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985;315:115-22.
13. Stewart TA, Pattengale PK, Leder P. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell 1984;38:627-37.
14. Jacks T, Remington L, Williams BO, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994;4:1-7.
15. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356:215-21.
16. Branda CS, Dymecki SM. Talking about a revolution: the impact of site-specific recombinases on genetic analyses in mice. Dev Cell 2004;6:7-28.
17. Johnson L, Mercer K, Greenbaum D, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001;410:1111-6.
18. Sweet-Cordero A, Mukherjee S, Subramanian A, et al. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet 2005;37:48-55.
19. Aguirre AJ, Bardeesy N, Sinha M, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 2003;17:3112-26.
20. Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005;7:469-83.
21. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309.